GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET
Launched by THE UNIVERSITY OF HONG KONG · Aug 21, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different approaches to improve the chances of having a baby for women undergoing in vitro fertilization (IVF) and frozen embryo transfer (FET). The trial compares the use of a hormone called GnRH agonist as a "dual trigger" during IVF to the traditional hCG trigger, to see which method leads to more live births. Additionally, it looks at how effective the GnRH agonist is for supporting the luteal phase (the time right after embryo transfer) compared to a placebo (a treatment that has no active ingredients) in women who are having FET.
To participate in this study, women must be under 43 years old and undergoing either IVF or FET using their own embryos. Certain conditions, like having used donor eggs or embryos, or specific health issues, might exclude someone from joining. Participants can expect to receive either the GnRH agonist or a placebo, depending on the group they are assigned to. The trial aims to help improve fertility treatments and ultimately increase the chances of a successful pregnancy for women facing subfertility challenges.
Gender
FEMALE
Eligibility criteria
- • IVF
- Inclusion criteria:
- • - Women aged \<43 years at the time of IVF treatment
- Exclusion criteria:
- • Preimplantation genetic diagnosis treatment
- • Use of donor oocytes or donor embryos
- • Hydrosalpinx shown on pelvic scanning and not surgically treated
- • Women at risk of OHSS
- • FET
- Inclusion criteria:
- • Women aged \<43 years at the time of IVF treatment
- • Replacing early cleavage embryos or blastocysts after thawing
- • FET in natural cycles
- Exclusion criteria:
- • Frozen early cleavage embryos thawed and cultured to blastocysts prior to transfer as requested by the patient
- • Preimplantation genetic diagnosis treatment
- • Use of donor oocytes or donor embryos
- • Hydrosalpinx shown on pelvic scanning and not surgically treated
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, Hong Kong, China
Patients applied
Trial Officials
Ernest HY Ng, MD
Principal Investigator
The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials